

Atty. Dkt. No. SPRUS1130 (064206-0601)
026470-0401



UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Christopher J. Ormandy et al.
Title: METHOD FOR INDUCING
MAMMARY EPITHELIAL
CELL DIFFERENTIATION
Appl. No.: 10/529,094
Filing Date: 09/25/2003
Examiner: Unknown
Art Unit: Unknown
Confirmation No. 1967

<p>CERTIFICATE OF MAILING</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below.</p> <p>Stephen E. Reiter, Reg. No. 31,192</p> <p>(Printed Name)</p> <p><i>Stephen E. Reiter</i></p> <p>(Signature)</p> <p>April 7, 2006</p> <p>(Date of Deposit)</p>

TRANSMITTAL

Mail Stop Sequence
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed please find the following:

1. Amendment in Response to Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.
2. Return copy of Notice to Comply.
3. Sequence Listing Paper Copy.
4. Computer Readable Form (CRF) copy of the Sequence Listing
5. Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§ 1.821-1.825
6. Power of Attorney by Assignee and Exclusion of Inventor Under Rule 37 CFR § 3.71.
7. Statement Claiming Small Entity Status (37 CFR 1.9(c-f) and 1.27(b-d).
8. Return postcard.

In re Application of
Christopher Ormandy et al.
Serial No. 10/529,094
Page 2 of 2

Atty. Dkt. No. SPRUS1130 (064206-0601)
026470-0401


No fee is deemed necessary in connection with this paper. However, if any fee is required, the Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17, and 1.21 that may be required by this transmittal, or to credit any overpayment, to **Deposit Account No. 50-0872.**

Respectfully submitted,

Date: April 7, 2006

FOLEY & LARDNER LLP
Customer Number: 30542
Telephone: (858) 847-6711
Facsimile: (858) 792-6773

By



Stephen E. Reiter
Attorney for Applicant
Registration No. 31,192



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/529,094	FIRST NAMED APPLICANT Christopher J Ormandy	ATTY. DOCKET NO. SPRUS1130 (064206-0601)
---	--	---

RECEIVED

FEB 16 2006

IP DEPT
FOLEY & LARDNER LLP

Done 4-13-06
DD-9-13-06

INTERNATIONAL APPLICATION NO.

PCT/AU03/01266

I.A. FILING DATE

PRIORITY DATE

09/25/2003

09/25/2002

CONFIRMATION NO. 1967

371 FORMALITIES LETTER



OC000000018032223

30542
FOLEY & LARDNER LLP
P.O. BOX 80278
SAN DIEGO, CA 92138-0278

Date Mailed: 02/13/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

SUMMARY OF FEES DUE:

Total additional fees required for this application is **\$-400** for a Small Entity:

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

(A previous payment of **\$400** will be applied to the additional fees indicated above.)

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

026470-0401

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

FRANCINE YOUNG

Telephone: (703) 308-9140 EXT 215

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/529,094	PCT/AU03/01266	SPRUS1130 (064206-0601)

FORM PCT/DO/EO/922 (371 Formalities Notice)